Format

Send to

Choose Destination
Sci Signal. 2014 Sep 23;7(344):ra90. doi: 10.1126/scisignal.2005504.

Fibroblast growth factor receptor 1 is a key inhibitor of TGFβ signaling in the endothelium.

Author information

1
Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA. michael.simons@yale.edu pei-yu.chen@yale.edu.
2
Department of Surgery, Yale University School of Medicine, New Haven, CT 06520, USA.
3
Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA. Department of Cell Biology, Yale University School of Medicine, New Haven, CT 06520, USA. michael.simons@yale.edu pei-yu.chen@yale.edu.

Abstract

Abnormal vascular homeostasis can lead to increased proliferation of smooth muscle cells and deposition of extracellular matrix, resulting in neointima formation, which contributes to vascular lumen narrowing, a pathology that underlies diseases including transplant vasculopathy, the recurrence of stenosis, and atherosclerosis. Growth of neointima is in part due to endothelial-to-mesenchymal transition (EndMT), a transforming growth factor-β (TGFβ)-driven process, which leads to increased numbers of smooth muscle cells and fibroblasts and deposition of extracellular matrix. We reported that endothelial cell-specific knockout of fibroblast growth factor receptor 1 (FGFR1) led to activation of TGFβ signaling and development of EndMT in vitro and in vivo. Furthermore, EndMT in human diseased vasculature correlated with decreased abundance of FGFR1. These findings identify FGFR1 as the key regulator of TGFβ signaling and EndMT development.

PMID:
25249657
DOI:
10.1126/scisignal.2005504
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center